Topical Quaternary Ammonium Composition for Viral Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections such as herpes, HIV, and adenovirus infections lack effective solutions to reduce symptom severity and duration, and there is a need for non-invasive, non-oral prophylaxis methods to prevent the spread of these infections.
Innovation Solution
A pharmaceutical composition containing C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is administered topically or otherwise to reduce symptom severity and duration of viral infections, and to prevent the spread of these infections by forming a barrier that inhibits viral entry and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for viral infections are used, then viral infections can be managed, but symptom severity and duration cannot be effectively reduced
Solution Approach 1:
The patent changes the chemical parameter of the antiviral agent by using C12-C14 alkyl chains instead of traditional longer-chain quaternary ammonium compounds. This parameter change results in improved viral inactivation effectiveness while reducing symptom duration, as the optimized chain length provides optimal balance between antiviral activity and biocompatibility
Solution Approach 2:
The invention creates a composite pharmaceutical composition combining C12-C14 alkyl(ethylbenzyl)dimethylammonium chloride with specific concentrations of other ingredients. This composite formulation achieves synergistic effects that reduce both symptom severity and duration more effectively than single-component treatments
2Reliability
If oral prophylaxis methods are used, then viral infection spread can be prevented, but patient compliance and convenience are reduced
Solution Approach 1:
The patent replaces the mechanical/physiological system of oral administration with a topical application system. The composition is applied topically to create a local barrier that prevents viral entry, eliminating the need for oral ingestion and significantly improving patient compliance while maintaining prevention effectiveness
Solution Approach 2:
The topical composition acts as an intermediary barrier between the virus and the host tissue. This intermediary layer physically blocks viral entry without requiring systemic absorption, providing effective prophylaxis through a non-invasive route that enhances patient compliance
Data Source
AI summary
Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis.